TB Alliance's Pretomanid Seems OK Heading To Advisory Cmte. As US FDA Showcases Regulatory Flexibility
Executive Summary
The Global Alliance for TB Drug Development is seeking an approval for pretomanid as part of an oral combination regimen for highly resistant tuberculosis.
You may also be interested in...
Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out
Achaogen can take solace in US FDA's approval of the aminoglycoside antibacterial for the treatment of complicated urinary tract infections, but the limited use indication for bloodstream infections was rejected.
FDA's Yim Wants US To Emulate Europe On Biosimilars
In an exclusive interview with Generics Bulletin sister publication the Pink Sheet, the now-permanent OTBB director Sarah Yim discussed her expectations for the future of the US biosimilars market, her learning experience as acting director and upcoming challenges for her office.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: